Targetgene Biotechnologies
Tel Aviv, Israel· Est.
Precision genome‑editing platform for curative cell‑based therapies targeting cancer, genetic and immune diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Precision genome‑editing platform for curative cell‑based therapies targeting cancer, genetic and immune diseases.
OncologyImmunologyGenetic Diseases
Technology Platform
TGEE (TargetGene Genome‑Editing Engine) uses a dual‑guide RNA system to achieve ultra‑high specificity and efficiency in genome editing, comparable in ease of use to CRISPR‑Cas9 but with markedly reduced off‑target activity.
Opportunities
Licensing TGEE to pharma partners for cell‑therapy programs and expanding into rare‑disease gene‑editing indications could unlock significant revenue streams.
Risk Factors
Demonstrating in‑vivo safety and efficacy, navigating complex regulatory pathways, and competing with rapidly advancing CRISPR‑based platforms pose major challenges.
Competitive Landscape
TargetGene competes with CRISPR‑Cas9, base editors, prime editors, and other dual‑guide platforms; its claimed off‑target reduction and flexibility are the primary differentiators.